CSL - CSL Limited
ASX
->
Healthcare
->
Biotechnology
Parkville,
Australia
Type: Equity
CSL price evolution
CSL
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1657 | $1657 | $1017 | |
| Short term investments | ||||
| Net receivables | $799.2 | $903.6 | $700.8 | $615.3 |
| Inventory | $462.4 | $426.3 | $399.8 | $361.7 |
| Total current assets | $2911.4 | $3152.1 | $3463.4 | $3408.1 |
| Long term investments | ||||
| Property, plant & equipment | $670.7 | $664.2 | $653.7 | $705.6 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $6478.4 | $6728.3 | $6645.9 | $6620 |
| Current liabilities | ||||
| Accounts payable | $327.3 | $363.4 | $322.9 | $245.5 |
| Deferred revenue | ||||
| Short long term debt | $944 | $944 | $1420 | |
| Total current liabilities | $1068.4 | $1089.7 | $1174.7 | $4718 |
| Long term debt | $1887.2 | $1887.2 | $1886.9 | $10687 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $3715.5 | $3724 | $3786.6 | $18142 |
| Shareholders' equity | ||||
| Retained earnings | $6655.3 | $6456.9 | $5784.8 | $5634 |
| Other shareholder equity | -$102.3 | -$113 | -$119.3 | $2723 |
| Total shareholder equity | $19401 | $19401 | $19162 | |
| (in millions $) | 30 Jun 2024 | 30 Jun 2023 | 30 Jun 2022 | 30 Jun 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1657 | $1548 | $10436.4 | $1808.8 |
| Short term investments | $4.8 | |||
| Net receivables | $2767 | $1936 | $1513.1 | $1648 |
| Inventory | $5964 | $5466 | $4333 | $3780.6 |
| Total current assets | $10768 | $9259 | $16460.7 | $7389.7 |
| Long term investments | $21.5 | |||
| Property, plant & equipment | $9658 | $9352 | $8308.6 | $7536 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $38022 | $36234 | $28346 | $18156.9 |
| Current liabilities | ||||
| Accounts payable | $867 | $820 | $591.8 | $523 |
| Deferred revenue | ||||
| Short long term debt | $944 | $1055 | $4494 | $473.8 |
| Total current liabilities | $4950 | $4608 | $7108.2 | $3103.6 |
| Long term debt | $11239 | $11172 | $5163.8 | $5333.1 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $18621 | $18408 | $13768.5 | $9775.6 |
| Shareholders' equity | ||||
| Retained earnings | $16012 | $14621 | $13503.4 | $12679.4 |
| Other shareholder equity | $2832 | $2688 | $590.3 | -$4298.1 |
| Total shareholder equity | $19401 | $17826 | $14577.5 | $8381.3 |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1333.6 | $1450.6 | $1096.5 | |
| Cost of revenue | ||||
| Gross Profit | $514.4 | $568.9 | $398.9 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $198 | $191.4 | $173.7 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $74.9 | $87.4 | $43.9 | |
| Interest expense | $4 | -$5 | -$10.7 | |
| Net income | ||||
| Net income | $244.3 | $711.1 | $191.9 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Jun 2024 | 30 Jun 2023 | 30 Jun 2022 | 30 Jun 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $14800 | $13310 | $10561.9 | $10310 |
| Cost of revenue | $7095 | $6466 | $4829.6 | $4466.7 |
| Gross Profit | $7705 | $6844 | $5732.3 | $5843.3 |
| Operating activities | ||||
| Research & development | $1428 | $1235 | $1156.2 | $1001.4 |
| Selling, general & administrative | $2381 | $2356 | $1608.7 | $1616 |
| Total operating expenses | $10904 | $10057 | $7594.5 | $7180 |
| Operating income | $3896 | $3253 | $2967.4 | $3130 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $661 | $419 | $524.9 | $588.1 |
| Interest expense | -$478 | -$410 | -$178 | |
| Net income | ||||
| Net income | $2642 | $2194 | $2254.7 | $2375 |
| Income (for common shares) | $2642 | $2194 | $2254.7 | $2375 |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $1508.9 | $1526.6 | -$32 | $352.4 |
| Financing activities | ||||
| Dividends paid | -$127.4 | -$81.7 | -$41.5 | -$160.3 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$1242.9 | -$741.9 | -$166.1 | -$1349.7 |
| Effect of exchange rate | -$0.6 | -$0.8 | -$0.7 | $1.5 |
| Change in cash and equivalents | $925.1 | $1130.8 | -$35.3 | $205.5 |
| (in millions $) | 30 Jun 2024 | 30 Jun 2023 | 30 Jun 2022 | 30 Jun 2021 |
|---|---|---|---|---|
| Net income | $2642 | $2194 | $2254.7 | $2963.1 |
| Operating activities | ||||
| Depreciation | $528 | $490 | $448 | $589.6 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $2764 | $2601 | $2628.7 | $3621.9 |
| Investing activities | ||||
| Capital expenditures | -$849 | -$1228 | -$1078.8 | -$1667.1 |
| Investments | ||||
| Total cash flows from investing | -$1259 | -$11843 | -$1636.1 | -$1673.2 |
| Financing activities | ||||
| Dividends paid | -$1192 | -$1085 | -$1038.7 | -$958 |
| Sale and purchase of stock | $40 | $34 | $4988.4 | $56.4 |
| Net borrowings | -$58 | $1661 | $3723.7 | -$496.7 |
| Total cash flows from financing | -$1284 | $456 | $7675.9 | -$1401.8 |
| Effect of exchange rate | $2 | -$22 | $12.8 | $31.9 |
| Change in cash and equivalents | $134 | -$8825 | $8604.3 | $578.8 |
News
Fundamentals
| Market cap | $12.64B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 45.40M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 5.86% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.96 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.73 |
| Quick ratio | 2.29 |